{
  "symbol": "KYMR",
  "company_name": "Kymera Therapeutics Inc",
  "ir_website": "https://investors.kymeratx.com/",
  "structured_data": [
    {
      "section_name": "News & Events",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://investors.kymeratx.com/news-events/press-releases",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb89191/themes/site/client_site_202/dist/img/Kymera_Images_Hero-Short_ir-portal-overview.png)\n\n# Press Releases\n\nYear All20242023202220212020201920182017\n\n2024\n\nDisplaying 1 - 10 of 37 \n\nNovember 26, 2024\n\nKymera Therapeutics to Participate in Upcoming December Investor Conferences\n\nWATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at\n\n[Read More](/news-releases/news-release-details/kymera-therapeutics-participate-upcoming-december-investor)\n\nNovember 05, 2024\n\nKymera Therapeutics to Participate in Upcoming November Investor Conferences\n\nWATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at\n\n[Read More](/news-releases/news-release-details/kymera-therapeutics-participate-upcoming-november-investor-0)\n\nOctober 31, 2024\n\nKymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update\n\nKT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to dose ranging Phase 2b studies to accelerate overall development timelines; completion\n\n[Read More](/news-releases/news-release-details/kymera-therapeutics-announces-third-quarter-2024-financial)\n\nOctober 24, 2024\n\nKymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases\n\nKT-621, an oral degrader, is the first STAT6 targeted medicine to enter clinical development, with the potential to address multiple immuno-inflammatory diseases KT-621 has demonstrated dupilumab-like activity and was well tolerated in a wide variety of preclinical models of TH2 diseases Phase 1\n\n[Read More](/news-releases/news-release-details/kymera-therapeutics-announces-dosing-first-participant-phase-1)\n\nOctober 23, 2024\n\nKymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31\n\nWATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report third quarter 2024 financial results on October 31, 2024,\n\n[Read More](/news-releases/news-release-details/kymera-therapeutics-report-third-quarter-2024-financial-results)\n\nOctober 23, 2024\n\nKymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium\n\nWATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that new preclinical data from its innovative TPD\n\n[Read More](/news-releases/news-release-details/kymera-therapeutics-announces-three-scientific-presentations)\n\nOctober 09, 2024\n\nKymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader\n\nKT-621 has demonstrated dupilumab-like activity and was well tolerated in a wide variety of preclinical models of TH2 diseases KT-621 is expected to start Phase 1 in October, with Phase 1 data in the first half of 2025 WATERTOWN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc.\n\n[Read More](/news-releases/news-release-details/kymera-therapeutics-announces-fda-clearance-investigational-0)\n\nSeptember 25, 2024\n\nKymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress\n\nKT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic disease KT-621 demonstrated strong degradation of STAT6 in human sensory neurons resulting in inhibition of IL-13-induced itch- and pain-related gene transcripts with\n\n[Read More](/news-releases/news-release-details/kymera-therapeutics-presents-preclinical-data-kt-621-potent)\n\nAugust 28, 2024\n\nKymera Therapeutics to Participate in Upcoming September Investor Conferences\n\nWATERTOWN, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats\n\n[Read More](/news-releases/news-release-details/kymera-therapeutics-participate-upcoming-september-investor-0)\n\nAugust 21, 2024\n\nKymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares\n\nWATERTOWN, Mass., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the closing of its upsized underwritten public\n\n[Read More](/news-releases/news-release-details/kymera-therapeutics-announces-closing-upsized-225-million-public)\n\nX CLOSE Search\n"
        },
        {
          "title": "Events",
          "url": "https://investors.kymeratx.com/news-events/events",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb89191/themes/site/client_site_202/dist/img/Kymera_Images_Hero-Short_ir-portal-overview.png)\n\n# Events\n\n## Upcoming Events\n\nDate | Event Details | Remind Me  \n---|---|---  \nDecember 3, 2024 1:00 PM EST |  [Piper Sandler 36th Annual Healthcare Conference ](/events/event-details/piper-sandler-36th-annual-healthcare-conference) [Click here for Webcast](https://event.webcasts.com/starthere.jsp?ei=1697347&tp_key=3deb147016) Location New York, NY  |  [Add to Outlook](/node/10981/ics) [Add to Google Calendar](https://www.google.com/calendar/render?action=TEMPLATE&text=Kymera%20Therapeutics%2C%20Inc.%20-%20Piper%20Sandler%2036th%20Annual%20Healthcare%20Conference%20&dates=20241203T180000Z/20241203T180000Z&details=Event%20Details%3A%20http%3A//investors.kymeratx.com/events/event-details/piper-sandler-36th-annual-healthcare-conference%0A%0AWebcast%3A%20https%3A//event.webcasts.com/starthere.jsp%3Fei%3D1697347&tp_key=3deb147016&location=New%20York%2C%20NY%20&trp=false&sprop=name%3A)  \nDecember 4, 2024 4:15 PM EST |  [7th Annual Evercore ISI HealthCONx Conference](/events/event-details/7th-annual-evercore-isi-healthconx-conference) [Click here for Webcast](https://wsw.com/webcast/evercore44/kymr/2402505) Location Coral Gables, FL |  [Add to Outlook](/node/10986/ics) [Add to Google Calendar](https://www.google.com/calendar/render?action=TEMPLATE&text=Kymera%20Therapeutics%2C%20Inc.%20-%207th%20Annual%20Evercore%20ISI%20HealthCONx%20Conference&dates=20241204T211500Z/20241204T211500Z&details=Event%20Details%3A%20http%3A//investors.kymeratx.com/events/event-details/7th-annual-evercore-isi-healthconx-conference%0A%0AWebcast%3A%20https%3A//wsw.com/webcast/evercore44/kymr/2402505&location=Coral%20Gables%2C%20FL&trp=false&sprop=name%3A)  \n  \n## Archived Events\n\nDate | Event Details  \n---|---  \nNovember 20, 2024 4:00 PM GMT |  [Jefferies London Healthcare Conference ](/events/event-details/jefferies-london-healthcare-conference) [Click here for Webcast](https://wsw.com/webcast/jeff315/kymr/1877820) Location London, UK  \nNovember 19, 2024 9:20 AM EST |  [6th Annual Wolfe Research Healthcare Conference ](/events/event-details/6th-annual-wolfe-research-healthcare-conference) [Click here for Webcast](https://players.brightcove.net/6285638718001/CsxhGkzZ9_default/index.html?videoId=6364905417112) Location New York, NY  \nNovember 18, 2024 11:30 AM EST |  [Stifel 2024 Healthcare Conference ](/events/event-details/stifel-2024-healthcare-conference) [Click here for Webcast](https://wsw.com/webcast/stifel96/kymr/2132930) Location New York, NY  \nNovember 14, 2024  |  [J.P. Morgan Equity Opportunities Forum](/events/event-details/jp-morgan-equity-opportunities-forum-0) Location Miami, FL   \nNovember 12, 2024 10:00 AM EST |  [Guggenheim Inaugural Healthcare Innovation Conference ](/events/event-details/guggenheim-inaugural-healthcare-innovation-conference) [Click here for Webcast](https://wsw.com/webcast/guggen/kymr/1973815) Location Boston, MA   \nOctober 31, 2024 8:30 AM EDT |  [Kymera Therapeutics Third Quarter 2024 Results Call](/events/event-details/kymera-therapeutics-third-quarter-2024-results-call) [Click here for Webcast](https://edge.media-server.com/mmc/p/natgr58h/)  \nSeptember 17, 2024 11:30 AM EDT |  [2024 Cantor Fitzgerald Global Healthcare Conference](/events/event-details/2024-cantor-fitzgerald-global-healthcare-conference) [Click here for Webcast](https://wsw.com/webcast/cantor22/kymr/2118465) Location New York, NY   \nSeptember 9, 2024 8:00 AM EDT |  [H.C. Wainwright 26th Annual Global Investment Conference](/events/event-details/hc-wainwright-26th-annual-global-investment-conference) [Click here for Webcast](https://journey.ct.events/view/5d000925-5935-4861-9a56-467b4f5b6cec) Location New York, NY  \nSeptember 5, 2024 3:20 PM EDT |  [Morgan Stanley 22nd Annual Global Healthcare Conference](/events/event-details/morgan-stanley-22nd-annual-global-healthcare-conference) [Click here for Webcast](https://cc.webcasts.com/morg007/090424a_js/?entity=36_CUO6ML0) Location New York, NY   \nSeptember 4, 2024 3:00 PM EDT |  [Wells Fargo 2024 Healthcare Conference](/events/event-details/wells-fargo-2024-healthcare-conference) [Click here for Webcast](https://cc.webcasts.com/well001/090424a_js/?entity=15_SXBRHXE) Location Boston, MA  \n  \nX CLOSE Search\n"
        },
        {
          "title": "Presentations",
          "url": "https://investors.kymeratx.com/news-events/presentations",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb89191/themes/site/client_site_202/dist/img/Kymera_Images_Hero-Short_ir-portal-overview.png)\n\n# Presentations\n\n## Corporate Presentations\n\nDate | Title  \n---|---  \nOctober 2024 |  [Kymera Corporate Presentation, October 2024](/static-files/126c7138-25e0-4d8f-b8f4-b2b684dd82ee)  \n  \n## Company Events\n\nDate | Title  \n---|---  \nJanuary 2024 |  [Kymera Immunology R&D Day Presentation, January 2024 ](/static-files/14265265-2ae6-4d80-b3a2-4a85d51e8f8d)  \nDecember 2022 |  [Kymera 2022 KT-474 and Oncology Pipeline Update](/static-files/22d3633b-9f54-4c9e-a9e9-545044d31968)  \nDecember 2021 |  [2021 R&D Day Presentation](/static-files/6432c27c-8dea-4226-b8e8-96cd58df4b84)  \n  \nX CLOSE Search\n"
        }
      ]
    },
    {
      "section_name": "SEC Filings",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://investors.kymeratx.com/sec-filings",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb89191/themes/site/client_site_202/dist/img/Kymera_Images_Hero-Short_ir-portal-overview.png)\n\n# SEC Filings\n\nGroup 3,4,5Annual FilingsCurrent ReportsMergers & AcquisitionsOtherProxy FilingsQuarterly FilingsRegistration Statements\n\nFiling year All20242023202220212020\n\nAll\n\nItems per page 102550\n\n10\n\n[Filing Date](?items_per_page=10&order=field_nir_sec_date_filed&sort=asc \"Sort By Filing Date\") | [Form](?items_per_page=10&order=field_nir_sec_form&sort=asc \"Sort By Form\") | [Description](?items_per_page=10&order=field_nir_sec_description&sort=asc \"Sort By Description\") | View  \n---|---|---|---  \nNov 14, 2024 |  [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0000902664-24-006520) |  An amendment to the SC 13G filing |  [View HTML](/node/10961/html) [0000902664-24-006520.pdf](/static-files/47e2e6ec-6dd0-4f89-9af4-28766f8da505) [0000902664-24-006520.rtf](/static-files/4ddded85-a37c-4fb3-9919-90c99dde1f46) [0000902664-24-006520.xls](/static-files/5bcdd089-1933-4db7-a7d0-b1f07654317d)  \nNov 14, 2024 |  [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0000080255-24-001463) |  An amendment to the SC 13G filing |  [View HTML](/node/10966/html) [0000080255-24-001463.pdf](/static-files/0ad45958-540b-4a1a-ab58-1baa44a440b0) [0000080255-24-001463.rtf](/static-files/e04927ac-b7a0-4cce-bb84-123e20991368)  \nNov 14, 2024 |  [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0001104659-24-119016) |  An amendment to the SC 13G filing |  [View HTML](/node/10971/html) [0001104659-24-119016.pdf](/static-files/68d0dd2c-74ee-41f5-86ca-340eeeb40a5b) [0001104659-24-119016.rtf](/static-files/7d5ad350-d2cd-4b41-ba4a-07d3608cb697) [0001104659-24-119016.xls](/static-files/3bebb3a8-c7c5-43fc-a58f-0d1c78b843b3)  \nNov 12, 2024 |  [SC 13G](/sec-filings/sec-filing/sc-13g/0000315066-24-002814) |  A statement of beneficial ownership of common stock by certain persons |  [View HTML](/node/10956/html) [0000315066-24-002814.pdf](/static-files/a74d4b90-947b-4915-84f6-7d1ad8a725e7) [0000315066-24-002814.rtf](/static-files/41239ad7-ae26-4f62-97d0-23e1232e45b5)  \nNov 08, 2024 |  [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0000902219-24-000489) |  An amendment to the SC 13G filing |  [View HTML](/node/10951/html) [0000902219-24-000489.pdf](/static-files/3c2f4365-6be4-4c58-b135-2bc234f78c26) [0000902219-24-000489.rtf](/static-files/751726bb-bf8e-40b8-943a-d16ea112dabd) [0000902219-24-000489.xls](/static-files/7fd52a47-899d-4dc2-8d00-a54608063d48)  \nOct 31, 2024 |  [8-K](/sec-filings/sec-filing/8-k/0000950170-24-119245) |  Report of unscheduled material events or corporate event |  [View HTML](/node/10901/html) [0000950170-24-119245.pdf](/static-files/46ac17fb-2990-4c2e-8e27-f09d9ae732f7) [0000950170-24-119245.rtf](/static-files/62ee996f-ce37-412b-99c9-412abf93d592) [0000950170-24-119245.xls](/static-files/f5806123-cf5b-4768-bd17-340c2a5d6091) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0000950170-24-119245)  \nOct 31, 2024 |  [10-Q](/sec-filings/sec-filing/10-q/0000950170-24-119249) |  Quarterly report which provides a continuing view of a company's financial position |  [View HTML](/node/10906/html) [0000950170-24-119249.pdf](/static-files/b089d959-9dab-42d6-8f1c-5dbf376b90c6) [0000950170-24-119249.rtf](/static-files/39cb346b-a705-4c6d-b117-570da62b18ec) [0000950170-24-119249.xls](/static-files/3c7a1c5a-3b0c-4c1a-80ed-6d44c1007efa) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0000950170-24-119249)  \nOct 31, 2024 |  [S-3ASR](/sec-filings/sec-filing/s-3asr/0001193125-24-248179) |  S-3ASR |  [View HTML](/node/10911/html) [0001193125-24-248179.pdf](/static-files/476c5cb2-dce4-4207-bc26-f4b19af735fb) [0001193125-24-248179.rtf](/static-files/eecedf92-9516-4572-9ecf-d18cbeac6b79) [0001193125-24-248179.xls](/static-files/4e0feda6-5707-4372-b353-44793760bf80)  \nSep 17, 2024 |  [144](/sec-filings/sec-filing/144/0001950047-24-007187) |  Filed by \"insiders\" prior intended sale of restricted stock. Non-EDGAR filing |  [View HTML](/node/10811/html) [0001950047-24-007187.pdf](/static-files/da2d78b4-23dd-4f38-b2e2-9603ff3bab21) [0001950047-24-007187.rtf](/static-files/43e77fa2-12cd-4db3-9b6e-f932afe6dada)  \nSep 17, 2024 |  [4](/sec-filings/sec-filing/4/0000950170-24-107458) |  Statement of changes in beneficial ownership of securities |  [View HTML](/node/10816/html) [0000950170-24-107458.pdf](/static-files/001db62e-266f-44b9-bcc3-e3dacc9695ab) [0000950170-24-107458.rtf](/static-files/341fbcfc-49ac-4bfd-be3b-9c60496c9ed5) [0000950170-24-107458.xls](/static-files/74a9d0c6-ae28-4e63-94a0-f11a8623c096)  \n  \nDisplaying 1 - 10 of 386 results\n\nData provided by [Kaleidoscope](https://www.kscope.io).\n\nX CLOSE Search\n"
        }
      ]
    },
    {
      "section_name": "Stock",
      "links": [
        {
          "title": "Stock Quote & Chart",
          "url": "https://investors.kymeratx.com/stock-information/stock-quote-chart",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb89191/themes/site/client_site_202/dist/img/Kymera_Images_Hero-Short_ir-portal-overview.png)\n\n# Stock Quote & Chart\n\n## Stock Quote\n\nChange\n\nVolume\n\nToday's Open\n\nPrevious Close\n\nToday's High\n\nToday's Low\n\n52 Week High\n\n52 Week Low\n\n## Stock Chart\n\nMinimum 15 minutes delayed. Source: LSEG\n\nX CLOSE Search\n"
        },
        {
          "title": "Historic Price Lookup",
          "url": "https://investors.kymeratx.com/stock-information/historic-price-lookup",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb89191/themes/site/client_site_202/dist/img/Kymera_Images_Hero-Short_ir-portal-overview.png)\n\n# Historic Price Lookup\n\nLookup Month JanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember\n\nNovember\n\nLookup Day 12345678910111213141516171819202122232425262728293031\n\n30\n\nLookup Year 20202021202220232024\n\n2024\n\nLeave this field blank\n\n## Week of November 25, 2024\n\nDate Requested | Open Price | Day High | Day Low | Closing Price | Volume | Split Adjustment Factor  \n---|---|---|---|---|---|---  \nNovember 25, 2024 | $45.41 | $48.29 | $45.38 | $47.02 | 545,608 | 1:1  \nNovember 26, 2024 | $46.92 | $47.57 | $44.75 | $45.98 | 967,461 | 1:1  \nNovember 27, 2024 | $46.05 | $47.73 | $46.05 | $46.86 | 388,380 | 1:1  \nNovember 29, 2024 | $47.00 | $47.09 | $46.31 | $46.85 | 184,881 | 1:1  \n  \n## Weekly Stock Data\n\nNOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shown. The closing price is not necessarily indicative of future price performance.\n\nMinimum 15 minutes delayed. Source: LSEG\n\nX CLOSE Search\n"
        },
        {
          "title": "Analyst Coverage",
          "url": "https://investors.kymeratx.com/stock-information/analyst-coverage",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb89191/themes/site/client_site_202/dist/img/Kymera_Images_Hero-Short_ir-portal-overview.png)\n\n# Analyst Coverage\n\nFirm | Analyst  \n---|---  \nB. Riley Securities |  Kalpit Patel   \nBofA Securities |  Tazeen Ahmed   \nBrookline Capital Markets |  Leah Cann   \nCowen |  Marc Frahm   \nGoldman Sachs |  Chris Shibutani   \nGuggenheim |  Michael Schmidt   \nHC Wainwright |  Andrew Fein   \nJefferies |  Kelly Shi   \nJP Morgan |  Eric Joseph   \nLeerink Partners |  Faisal Khurshid   \nMorgan Stanley |  Vikram Purohit   \nOppenheimer & Co. Inc. |  Jeff Jones   \nPiper Sandler  |  Edward A. Tenthoff   \nStephens |  Sudan Loganathan   \nStifel |  Bradley Canino   \nTruist Securities  |  Kripa Devarakonda   \nUBS Securities |  Eliana Merle   \nWells Fargo |  Derek Archila   \nWolfe Research  |  Andy Chen   \n  \nKymera Therapeutics, Inc. is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Kymera Therapeutics, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Kymera Therapeutics, Inc. or its management. Kymera Therapeutics, Inc. does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.\n\nX CLOSE Search\n"
        }
      ]
    },
    {
      "section_name": "Corporate Governance",
      "links": [
        {
          "title": "Documents & Charters",
          "url": "https://investors.kymeratx.com/corporate-governance/documents-charters",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb89191/themes/site/client_site_202/dist/img/Kymera_Images_Hero-Short_ir-portal-overview.png)\n\n# Documents & Charters\n\n## Corporate Governance Overview\n\nThe Board of Directors of Kymera Therapeutics (the \"Company\") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.\n\n## Governance Documents\n\n[Code of Business Conduct and Ethics](/static-files/51fd1f5a-9ffc-402a-bedb-cf35308c0af3)\n\n[Corporate Governance Guidelines](/static-files/15291c32-b352-48a2-883d-0304984c98b7)\n\n## Committee Charters\n\n[Audit Committee](/static-files/abee8883-ab7b-4bcd-8db1-da434fa13ae9)\n\n[Compensation and Talent Committee](/static-files/b4b2e289-d98e-44cd-b02a-77abd2a5fa71)\n\n[Nominating and Corporate Governance Committee](/static-files/59032e56-d609-4717-919c-81d27c8fac20)\n\nX CLOSE Search\n"
        },
        {
          "title": "Board of Directors",
          "url": "https://www.kymeratx.com/about-us/leadership/",
          "content": "![Kymera_Images_Leadership_Hero](https://www.kymeratx.com/wp-content/uploads/2023/12/Kymera_Images_Leadership_Hero-scaled.webp)\n\n![](/wp-content/uploads/2023/11/hero-pattern-short.png)\n\nOur Leadership \n\n#  A Team of Passionate Leaders \n\nKymera is led by a seasoned team of established biopharmaceutical leaders with the insights and experience to accelerate our progress and change patient lives.\n\nJoin Our Exceptional Team \n\nWe welcome like-minded pioneers to join us on our extraordinary journey as we create a culture where diverse perspectives are invited and collaboration is celebrated—all in service of our goal to revolutionize medicine and change patients’ lives. \n\n[View Open Positions](https://www.kymeratx.com/careers-culture/working-at-kymera/#open-positions)\n\n  * [Management Team](#management)\n  * [Board of Directors](#board)\n\n\n\n## Management Team\n\nKymera’s leadership are all dedicated innovators, each with decades of experience in drug discovery, development, and growing companies. \n\n![Kymera_Images_Leadership_Headshot_Nello-Mainolfi-PhD](https://www.kymeratx.com/wp-content/uploads/2023/12/Kymera_Images_Leadership_Headshot_Nello-Mainolfi-PhD.webp)\n\nNello Mainolfi, Ph.D. \n\nFounder, President & CEO \n\n[View Bio](https://www.kymeratx.com/about-us/leadership/nello-mainolfi-phd/)\n\n![Kymera_Images_Leadership_Headshot_Jeremy-Chadwick-PhD](https://www.kymeratx.com/wp-content/uploads/2023/12/Kymera_Images_Leadership_Headshot_Jeremy-Chadwick-PhD.webp)\n\nJeremy Chadwick, Ph.D. \n\nChief Operating Officer \n\n[View Bio](https://www.kymeratx.com/about-us/leadership/jeremy-chadwick-phd/)\n\n![Kymera_Images_Leadership_Headshot_Ellen-Chiniara-JD](https://www.kymeratx.com/wp-content/uploads/2023/12/Kymera_Images_Leadership_Headshot_Ellen-Chiniara-JD.webp)\n\nEllen Chiniara, JD \n\nChief Legal Officer and Corporate Secretary \n\n[View Bio](https://www.kymeratx.com/about-us/leadership/ellen-chiniara-jd/)\n\n![Kymera_Images_Leadership_Headshot_Jared-Gollob-MD](https://www.kymeratx.com/wp-content/uploads/2023/12/Kymera_Images_Leadership_Headshot_Jared-Gollob-MD.webp)\n\nJared Gollob, MD \n\nChief Medical Officer \n\n[View Bio](https://www.kymeratx.com/about-us/leadership/jared-gollob-md/)\n\n![Kymera_Images_Leadership_Headshot_Bruce-Jacobs-CFA-MBA](https://www.kymeratx.com/wp-content/uploads/2023/12/Kymera_Images_Leadership_Headshot_Bruce-Jacobs-CFA-MBA.webp)\n\nBruce Jacobs, CFA, MBA \n\nChief Financial Officer \n\n[View Bio](https://www.kymeratx.com/about-us/leadership/bruce-jacobs-cfa-mba/)\n\n![Kymera_Images_Leadership_Headshot_Karen-Weisbach](https://www.kymeratx.com/wp-content/uploads/2023/12/Kymera_Images_Leadership_Headshot_Karen-Weisbach.webp)\n\nKaren Weisbach \n\nHead of People and Culture \n\n[View Bio](https://www.kymeratx.com/about-us/leadership/karen-weisbach-2/)\n\n![Kymera_Images_Leadership_Headshot_Juliet-Williams-PhD](https://www.kymeratx.com/wp-content/uploads/2023/12/Kymera_Images_Leadership_Headshot_Juliet-Williams-PhD.webp)\n\nJuliet Williams, Ph.D. \n\nHead of Research \n\n[View Bio](https://www.kymeratx.com/about-us/leadership/juliet-williams-phd/)\n\n## Board of Directors\n\nOur board is composed of leaders with the experience and perspective to support Kymera’s evolution as we work to improve patients’ lives. \n\nNello Mainolfi, Ph.D. \n\nFounder, President & CEO \n\n[View Bio](https://www.kymeratx.com/about-us/leadership/nello-mainolfi-phd/)\n\nBruce Booth, DPhil \n\nChairman and Co-Founder \n\n[View Bio](https://www.kymeratx.com/about-us/leadership/bruce-booth-dphil/)\n\nFelix J. Baker, PhD \n\nLead Independent Director \n\n[View Bio](https://www.kymeratx.com/about-us/leadership/felix-j-baker-ph-d/)\n\nJeff Albers, JD, MBA \n\n[View Bio](https://www.kymeratx.com/about-us/leadership/jeff-albers-jd-mba/)\n\nPamela Esposito, PhD \n\n[View Bio](https://www.kymeratx.com/about-us/leadership/john-maraganore-phd/)\n\nGorjan Hrustanovic, PhD \n\n[View Bio](https://www.kymeratx.com/about-us/leadership/gorjan-hrustanovic-phd/)\n\nJohn Maraganore, PhD \n\n[View Bio](https://www.kymeratx.com/about-us/leadership/john-maraganore-phd-2/)\n\nLeigh Morgan \n\n[View Bio](https://www.kymeratx.com/about-us/leadership/leigh-morgan/)\n\nVictor Sandor, MDCM \n\n[View Bio](https://www.kymeratx.com/about-us/leadership/victor-sandor-mdcm/)\n\nElena Ridloff, CFA \n\n[View Bio](https://www.kymeratx.com/about-us/leadership/elena-ridloff-cfa/)\n\n![Kymera_Images_Leadership_Full-Bleed](https://www.kymeratx.com/wp-content/uploads/2023/12/Kymera_Images_Leadership_Full-Bleed-scaled.webp)\n\n# Join Us on Our Mission\n\nWe are a team of pioneers dedicated to reinventing the treatment of human disease and reshaping the landscape of healthcare.\n\n[Learn More About Our Approach](https://www.kymeratx.com/science-innovation/our-approach/)\n\nCompany Stats \n\nKymera is building a fully integrated medicines company to redefine disease treatment.\n\n90% \n\nof employees take pride in working at Kymera \n\n500+ \n\nissued or pending patents \n\n>$1B \n\ncapital raised to advance our pipeline \n\n1st \n\ndegrader targeting immunological diseases in clinical studies \n\n[Learn More About Kymera Perspectives](https://www.kymeratx.com/kymera-perspectives/)\n\n![Kymera_Images_Leadership_CTA_Our-Leadership](https://www.kymeratx.com/wp-content/uploads/2023/12/Kymera_Images_Leadership_CTA_Our-Leadership-scaled.webp)\n\nOur Leadership is Driving the Field Forward \n\nKymera’s team is catalyzing progress in the science of TPD with key publications and presentations that unlock insights and showcase our findings.\n\nDecember 10, 2023 \n\nPreliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors \n\n_American Society of Hematology (ASH) Annual Meeting and Exposition 2024_\n\n[See More](https://www.kymeratx.com/science-innovation/resource-library/resource/preliminary-safety-pharmacokinetics-pharmacodynamics-and-clinical-activity-of-kt-333-a-targeted-protein-degrader-of-stat3-in-patients-with-relapsed-or-refractory-lymphomas-large-granular-lymphocy/)\n\nNovember 14, 2023 \n\nIRAK4 Degradation vs Inhibition \n\n_IRAK4 Program Background_\n\n[See More](https://www.kymeratx.com/science-innovation/resource-library/resource/irak4-degradation-vs-inhibition/)\n\nNovember 13, 2023 \n\nNature Medicine: IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial \n\n_Lindsay Ackerman, Gerard Acloque, Sandro Bacchelli, Howard Schwartz, Brian J. Feinstein, et al._\n\n[See More](https://www.kymeratx.com/science-innovation/resource-library/resource/nature-medicine-irak4-degrader-in-hidradenitis-suppurativa-and-atopic-dermatitis-a-phase-1-trial/)\n\n[View All Scientific Resources](https://www.kymeratx.com/science-innovation/resource-library/)\n"
        },
        {
          "title": "Committee Composition",
          "url": "https://investors.kymeratx.com/corporate-governance/committee-composition",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb89191/themes/site/client_site_202/dist/img/Kymera_Images_Hero-Short_ir-portal-overview.png)\n\n# Committee Composition\n\nDirector Name | [Audit Committee](/static-files/abee8883-ab7b-4bcd-8db1-da434fa13ae9) | [Compensation Committee](/static-files/b4b2e289-d98e-44cd-b02a-77abd2a5fa71) | [Nominating and Corporate Governance Committee](/static-files/59032e56-d609-4717-919c-81d27c8fac20)  \n---|---|---|---  \nJeff Albers  | Member of the [Audit Committee](/static-files/abee8883-ab7b-4bcd-8db1-da434fa13ae9) | Chair of the [Compensation Committee](/static-files/b4b2e289-d98e-44cd-b02a-77abd2a5fa71)  \nPamela Esposito  | Member of the [Audit Committee](/static-files/abee8883-ab7b-4bcd-8db1-da434fa13ae9) | Member of the [Nominating and Corporate Governance Committee](/static-files/59032e56-d609-4717-919c-81d27c8fac20)  \nGorjan Hrustanovic  | Member of the [Nominating and Corporate Governance Committee](/static-files/59032e56-d609-4717-919c-81d27c8fac20)  \nJohn Maraganore  | Member of the [Compensation Committee](/static-files/b4b2e289-d98e-44cd-b02a-77abd2a5fa71)  \nLeigh Morgan  | Member of the [Compensation Committee](/static-files/b4b2e289-d98e-44cd-b02a-77abd2a5fa71) | Chair of the [Nominating and Corporate Governance Committee](/static-files/59032e56-d609-4717-919c-81d27c8fac20)  \nElena Ridloff  | Chair of the [Audit Committee](/static-files/abee8883-ab7b-4bcd-8db1-da434fa13ae9)  \n  \nLegend = Chair = Member\n\nX CLOSE Search\n"
        }
      ]
    },
    {
      "section_name": "Shareholder Resources",
      "links": [
        {
          "title": "Investor FAQs",
          "url": "https://investors.kymeratx.com/shareholder-resources/investor-faqs",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb89191/themes/site/client_site_202/dist/img/Kymera_Images_Hero-Short_ir-portal-overview.png)\n\n# Investor FAQs\n\n[Show All](#)\n\nPress space to expand and collapse this section\n\nWhere is Kymera Therapeutics’ corporate headquarters? \n\nKymera Therapeutics’ headquarters are located at 500 North Beacon Street, 4th Floor, Watertown, MA 02472.\n\nPress space to expand and collapse this section\n\nWhen was Kymera Therapeutics founded? \n\nKymera Therapeutics was founded in 2016.\n\nPress space to expand and collapse this section\n\nWhere is the Company incorporated?\n\nKymera Therapeutics is incorporated in Delaware.\n\nPress space to expand and collapse this section\n\nWhen did Kymera Therapeutics go public?\n\nKymera Therapeutics completed its IPO on August 20, 2020.\n\nPress space to expand and collapse this section\n\nWhat is Kymera Therapeutics’ fiscal year?\n\nKymera Therapeutics' fiscal year ends December 31st.\n\nPress space to expand and collapse this section\n\nHow is Kymera Therapeutics’ stock traded?\n\nKymera Therapeutics’ common stock is listed on the NASDAQ Market under the symbol “KYMR”.\n\nPress space to expand and collapse this section\n\nWho is Kymera Therapeutics’ transfer agent? \n\nThe transfer agent and registrar for the common stock of Kymera Therapeutics’ stock is:\n\nComputershare Trust Company, N.A. 250 Royall Street Canton, MA 02021 (800) 962-4284\n\nPress space to expand and collapse this section\n\nWhom do I contact with questions about my stock?\n\nFor questions about your stock please contact our transfer agent, Computershare Trust Company, N.A..\n\nPress space to expand and collapse this section\n\nHow do I transfer stock, change the address on my shareholder account, or replace a lost stock certificate?\n\nTo change the address on your shareholder account you must send both your old and new addresses to our transfer agent, Computershare Trust Company, N.A., 250 Royall Street, Canton, Massachusetts 02021.\n\nTo transfer stock or replace a lost stock certificate, contact our transfer agent, Computershare Trust Company, N.A. \n\nPress space to expand and collapse this section\n\nWho is Company's auditor?\n\nThe auditor for Kymera Therapeutics is Ernst & Young LLP located in Boston, MA.\n\nPress space to expand and collapse this section\n\nWho is the Company’s legal counsel?\n\nLegal counsel for Kymera Therapeutics is Goodwin Procter LLP, located in Boston, MA.\n\nPress space to expand and collapse this section\n\nWhere can I find out more about Kymera Therapeutics?\n\nTo find out more about Kymera Therapeutics visit their webpage at [www.kymeratx.com](https://www.kymeratx.com/).\n\nPress space to expand and collapse this section\n\nWhere can I get the latest corporate news releases and financial reports?\n\nKymera Therapeutics’ [press release archive](/news-events/press-releases) can be viewed under the “News & Events” section of the “Investors” page and financial reports are available under the “[SEC Filings](/sec-filings)” section located at our website: [www.kymeratx.com](https://www.kymeratx.com/).\n\nPress space to expand and collapse this section\n\nHow can I view documents Kymera Therapeutics has filed with the Securities & Exchange Commission (SEC), including Forms 10-K and 10-Q?\n\nKymera Therapeutics’ SEC Filings can be found on [www.sec.gov](https://www.sec.gov/) and are also available under the “SEC Filings” section of the “Investors” page located at our website [www.kymeratx.com](https://www.kymeratx.com/).\n\nPress space to expand and collapse this section\n\nWho makes up the Kymera Therapeutics Executive Management team and Board of Directors?\n\nFor a list of the Management team and Board of Directors, please visit the “[About Us](https://www.kymeratx.com/about-us/leadership/)” section of our website.\n\nPress space to expand and collapse this section\n\nWhom should I contact regarding investor inquiries?\n\nFor investor inquiries, please contact:\n\nJustine Koenigsberg Vice President, Investor Relations investors@kymeratx.com\n\nX CLOSE Search\n"
        },
        {
          "title": "Email Alerts",
          "url": "https://investors.kymeratx.com/shareholder-resources/email-alerts",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb89191/themes/site/client_site_202/dist/img/Kymera_Images_Hero-Short_ir-portal-overview.png)\n\n# Email Alerts\n\nTo opt-in for Kymera Therapeutics, Inc. email alerts, please select at least one alert option and enter your email address in the field below. After submitting your request, an activation email will be sent to the address provided. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time. By opting in for email alerts, you agree to the [Terms of Use](https://www.kymeratx.com/terms-of-use/) and [Privacy Policy](https://www.kymeratx.com/privacy-policy/). If you would like to opt out of email alerts, you can [unsubscribe here](/unsubscribe). \n\nRequired fields denoted by an asterisk ().\n\nHide lower priority columns\n\nAlert Type  \n---  \nEnd-of-Day Stock Quote  \nSEC Filings  \nEvents  \nNews  \nWeekly Summary  \n  \nEmail\n\nLeave this field blank\n\nX CLOSE Search\n"
        },
        {
          "title": "Contacts",
          "url": "https://investors.kymeratx.com/shareholder-resources/contacts",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb89191/themes/site/client_site_202/dist/img/Kymera_Images_Hero-Short_ir-portal-overview.png)\n\n# Contacts\n\n## Investor & Media Contact\n\nJustine Koenigsberg Vice President, Investor Relations investors@kymeratx.com\n\nTo request information, please fill out and submit the form below.\n\nName\n\nEmail\n\nSubject\n\nComments\n\nLeave this field blank\n\nX CLOSE Search\n"
        }
      ]
    },
    {
      "section_name": "Featured Presentations",
      "links": [
        {
          "title": "Kymera Corporate Presentation, October 2024",
          "url": "https://investors.kymeratx.com/static-files/d6f47faa-977c-4835-91fe-a582faeaaf85",
          "content": "\n"
        },
        {
          "title": "Kymera Immunology R&D Day Presentation, January 2024",
          "url": "https://investors.kymeratx.com/static-files/14265265-2ae6-4d80-b3a2-4a85d51e8f8d",
          "content": "\n"
        }
      ]
    }
  ]
}